PLP2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

	Compound	Confidence	Supporting neighbours

Clinical trials — most relevant to PLP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy	PHASE4	COMPLETED
AntiCoagulants and COGnition	PHASE4	UNKNOWN
D-Cycloserine for Serine Palmitoyltransferase Inhibition	PHASE4	COMPLETED
Intravenous Immunoglobulin Therapy in Optic Neuritis	PHASE3	COMPLETED
T Cell Vaccination in Patients With Progressive Multiple Sclerosis	PHASE1/PHASE2	COMPLETED
Cytotron® Delivered Rotational Field Quantum Nuclear Magnetic Resonance Therapy for Multiple Sclerosis	PHASE2	UNKNOWN
Study to Identify the Genetic Variations Associated With Phantom Limb Pain	nan	COMPLETED
Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus	nan	UNKNOWN
Genetics and Phantom Limb Pain	nan	WITHDRAWN
The Classification and Cause of Leukodystrophies of Unknown Cause	nan	COMPLETED
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies	nan	COMPLETED
Natural History of the Leukodystrophies	nan	COMPLETED
Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease	nan	RECRUITING
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
Consequences of Mutations in the SPG7 Gene at the Heterozygous State	nan	COMPLETED
The Myelin Disorders Biorepository Project	nan	RECRUITING
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
SNAP: Measurement of the Subjective Perception of the Symptom in Hereditary Spastic Paraparesis (HSP)	nan	COMPLETED
The Nosology and Etiology of Leukodystrophies of Unknown Causes	nan	COMPLETED
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others	nan	RECRUITING
Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological Matrices	nan	ACTIVE_NOT_RECRUITING
Characterisation of Adult-Onset Hypophosphatasia	nan	COMPLETED
Protein Synthesis in the Brain of Patients With Fragile X Syndrome	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
Initial Clinical Presentation of Inflammatory Optic Neuritis Associated or Not With Autoantibodies Anti-Myelin-oligodendrocyte-glycoprotein	nan	COMPLETED
Identification of a New Gene Involved in Hereditary Lipodystrophy	nan	COMPLETED
Natural History Study of Patients With Hypophosphatasia (HPP)	nan	RECRUITING
Volumetrics and Proteomics in Shunted Normal Pressure Hydrocephalus	nan	UNKNOWN
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte	nan	COMPLETED
Clinical Diagnosis of Acute Porphyria	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PLP2 binder may also engage these)

Protein	Name	Similarity
Q6Y1E2	—	0.993	Q6Y1E2 →
Q95MN6	—	0.991	Q95MN6 →
Q9D6G9	—	0.978	Q9D6G9 →
Q9CZR4	—	0.968	Q9CZR4 →
Q96FZ5	—	0.963	Q96FZ5 →
Q6P742	—	0.962	Q6P742 →
A2VE13	—	0.959	A2VE13 →
MAL2	Protein MAL2	0.957	landscape →
O09198	—	0.956	O09198 →
Q28296	—	0.955	Q28296 →
Q5RAI2	—	0.954	Q5RAI2 →
Q99LJ5	—	0.954	Q99LJ5 →
Q64349	—	0.950	Q64349 →
Q1RMP9	—	0.949	Q1RMP9 →
P21145	—	0.947	P21145 →
MYADM	Myeloid-associated differentiation marker	0.945	landscape →
Q8BI08	—	0.945	Q8BI08 →
Q5R6H1	—	0.940	Q5R6H1 →
Q8CJ61	—	0.940	Q8CJ61 →
Q3ZBY0	—	0.939	Q3ZBY0 →
Q9R1Q7	—	0.939	Q9R1Q7 →
Q96MX0	—	0.938	Q96MX0 →
P20274	—	0.933	P20274 →
Q9ESD6	—	0.932	Q9ESD6 →
Q8IZV2	—	0.932	Q8IZV2 →
P56563	—	0.930	P56563 →
D4A9I3	—	0.929	D4A9I3 →
P54825	—	0.928	P54825 →
Q9Y5I7	—	0.928	Q9Y5I7 →
SLC44A1	Choline transporter-like protein 1	0.928	landscape →